全文获取类型
收费全文 | 11204篇 |
免费 | 1055篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 213篇 |
儿科学 | 287篇 |
妇产科学 | 537篇 |
基础医学 | 1560篇 |
口腔科学 | 345篇 |
临床医学 | 1152篇 |
内科学 | 2487篇 |
皮肤病学 | 99篇 |
神经病学 | 1474篇 |
特种医学 | 316篇 |
外国民族医学 | 1篇 |
外科学 | 1512篇 |
综合类 | 184篇 |
一般理论 | 2篇 |
预防医学 | 657篇 |
眼科学 | 232篇 |
药学 | 626篇 |
中国医学 | 1篇 |
肿瘤学 | 582篇 |
出版年
2021年 | 114篇 |
2019年 | 126篇 |
2018年 | 147篇 |
2017年 | 129篇 |
2016年 | 115篇 |
2015年 | 143篇 |
2014年 | 192篇 |
2013年 | 317篇 |
2012年 | 412篇 |
2011年 | 443篇 |
2010年 | 262篇 |
2009年 | 275篇 |
2008年 | 392篇 |
2007年 | 431篇 |
2006年 | 445篇 |
2005年 | 435篇 |
2004年 | 403篇 |
2003年 | 375篇 |
2002年 | 402篇 |
2001年 | 363篇 |
2000年 | 370篇 |
1999年 | 283篇 |
1998年 | 105篇 |
1997年 | 112篇 |
1996年 | 104篇 |
1994年 | 90篇 |
1993年 | 88篇 |
1992年 | 251篇 |
1991年 | 254篇 |
1990年 | 281篇 |
1989年 | 280篇 |
1988年 | 275篇 |
1987年 | 269篇 |
1986年 | 239篇 |
1985年 | 274篇 |
1984年 | 213篇 |
1983年 | 164篇 |
1982年 | 127篇 |
1981年 | 132篇 |
1979年 | 199篇 |
1978年 | 157篇 |
1977年 | 133篇 |
1976年 | 108篇 |
1975年 | 96篇 |
1974年 | 159篇 |
1973年 | 146篇 |
1972年 | 117篇 |
1971年 | 105篇 |
1970年 | 108篇 |
1969年 | 96篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
Most studies that have examined minimally invasive, encapsulated, follicular carcinoma (FC) or Hurthle cell carcinomas (HCs) have contained only a few metastatic neoplasms. We studied 34 patients with a single, minimally invasive, metastatic FC or HC and compared them with 38 patients with similar, nonmetastatic FCs or HCs. The numbers of incomplete capsular penetration (neoplasm into but not through the capsule), complete capsular penetration (neoplasm through the capsule), and vascular invasion foci were quantified. The median number (three), range, and distribution of complete capsular penetration and vascular invasion foci were similar in the nonmetastatic and metastatic carcinomas. All of the metastatic FCs and HCs had at least one vascular invasion or complete capsular penetration focus. Sixty-two percent of the metastatic carcinomas had two to four complete capsular penetration foci, and 60% had two to four vascular invasion foci. Two metastatic neoplasms had incomplete capsular penetration but had one and two vascular invasion foci, respectively. One tumor had no vascular invasion but had four complete capsular penetration foci. No metastatic neoplasms had incomplete capsular penetration only. There were no differences in the number of vascular invasion or complete capsular penetration foci between metastatic and nonmetastatic FCs and HCs and between metastatic FCs and HCs. Most metastatic neoplasms had vascular space invasion and complete capsular penetration. The number of complete capsular penetration or vascular invasion foci was not associated with the initial site of metastasis or the interval between the surgery and the metastasis. 相似文献
994.
A Recht S E Come R S Gelman M Goldstein S Tishler S M Gore A L Abner F A Vicini B Silver J L Connolly 《Journal of clinical oncology》1991,9(9):1662-1667
The optimal means of combining breast-conserving surgery, radiation therapy, and chemotherapy for the treatment of patients with early-stage, node-positive breast cancer is not known. We reviewed the results in 295 patients treated at the Joint Center for Radiation Therapy and affiliated institutions from 1976 to 1985. All patients had positive axillary nodes on dissection, had no gross residual disease in the breast or axilla after surgery, and received breast irradiation (with or without nodal irradiation) and three or more cycles of a cyclophosphamide, methotrexate, and fluorouracil (CMF)-based or doxorubicin-containing regimen. Median follow-up in patients without any failure was 78 months. Breast failure rates were assessed in relation to the sequencing of radiotherapy and chemotherapy. The different sequences were not randomly assigned, and the characteristics of the sequence groups differed. The actuarial 5-year breast failure rate was 4% in 99 patients receiving radiotherapy before chemotherapy; 8% in 54 patients sequentially receiving some chemotherapy, then radiotherapy without concurrent chemotherapy, then further chemotherapy; and 6% in 116 patients receiving concurrent chemotherapy and radiotherapy. However, the failure rate was 41% in 26 patients who received all chemotherapy before radiotherapy. The crude incidences of local failure within 4 years of treatment in these groups were 3%, 2%, 4%, and 15%, respectively (P = .065 for all four groups not being the same). The actuarial 5-year local failure rate was 5% for 252 patients irradiated within 16 weeks after surgery compared with 35% for 34 patients irradiated more than 16 weeks after surgery. The 4-year crude incidences were 4% and 12% for the two groups, respectively (P = .06). These results suggest that delaying the initiation of radiotherapy may result in an increased likelihood of local failure. Formal randomized controlled trials will be needed to confirm these results and to improve the integration of these treatment modalities. 相似文献
995.
M B Goldstein R Bear R M Richardson P A Marsden M L Halperin 《The American journal of the medical sciences》1986,292(4):198-202
In patients with a normal plasma anion gap type of metabolic acidosis, knowledge of the rate of ammonium excretion can provide valuable information to determine if there is a renal cause for the disorder. Unfortunately, few hospital biochemistry laboratories offer routine determination of the urine ammonium concentration. Data are presented that demonstrate a direct linear relationship between the urine anion gap (Na+ + K+ - Cl-) and the urine ammonium concentration. In a 24-hour urine collection, the relationship is urine ammonium equals -0.8 (urine anion gap) +82 (r = 0.97 p less than 0.01). The applications of this index of ammonium excretion are discussed. 相似文献
996.
997.
A L Goldstein R S Schulof P H Naylor N R Hall 《Medical oncology and tumor pharmacotherapy》1986,3(3-4):211-221
For years, scientists have searched for ways to trigger the body's own defenses against cancer and other diseases associated with abnormal immunity. This search has led to the discovery of a number of important new biological and chemical substances that augment, direct or restore many of the normal defenses of the body. These substances are in essence the natural drugs of the body that endow us with immunity and resistance to disease. Now called biological response modifiers (BRMs), most of these 'new medicines', such as thymosins, lymphokines, and interferons, occur naturally in the body, while others, synthetic immunomodulators and thymomimetic agents (drugs that mimic thymic function) have been created in the laboratory. Previously, therapeutic drug development in this area relied upon chemical synthesis or introduction of bacterial adjuvants, or modified viral compounds and substances, which were foreign to the body. Therefore, they did not and do not rely upon or use the body's natural immune and biological response systems for protection against disease, function and response to the environment. Although scientists have known about BRMs for years, isolating and purifying them so that they could be used to treat diseases has been extremely difficult. Many of these substances, such as the lymphokines, occur in the body in minute amounts and normally do not circulate in the blood. The development of new technologies for isolation and large scale synthesis, e.g. solid phase peptide synthesis, high-pressure liquid chromatography microsequencing and genetic engineering, has now permitted scientists to isolate, purify, and synthesize BRMs in sufficiently large quantities to allow human clinical trials. In this paper we will focus on the potential clinical applications of the thymosins and anti-thymosins. 相似文献
998.
Michael I. Goldstein T. E. Lacher B. Woodbridge M. J. Bechard S. B. Canavelli M. E. Zaccagnini G. P. Cobb E. J. Scollon R. Tribolet M. J. Hopper 《Ecotoxicology (London, England)》1999,8(3):201-214
Swainson's hawks (Buteo swainsoni) were observed in the grasslands (pampas) of Argentina during the austral summer of 1995–96. Widespread agrochemical use to control insects had a profound effect on flocks of hawks foraging on grasshoppers and caterpillars throughout the pampas. We describe 19 mortality incidents and an estimated 5,095 dead hawks. Forensic analysis indicated that the organophosphate insecticide monocrotophos was responsible for the deaths at six separate sites, accounting for over 4,000 of the mortalities. Brain cholinesterase was lethally inhibited (>95%) and monocrotophos residues (n=31/45, mean=0.20 ppm, range 0.05–1.08 ppm) were found in the contents of the gastrointestinal tract. No other insecticide residues were found. Sample analyses, combined with interviews with farmers, indicated that monocrotophos was responsible for deaths at 17 of 19 mortality incidents.Novartis Crop Protection AG, Residue Analysis 相似文献
999.
Amanda Peltier MD A. Gordon Smith MD James W. Russell MD MS Kiran Sheikh MD Billie Bixby BS James Howard BS Jonathan Goldstein MD Yanna Song MS Lily Wang PhD Eva L. Feldman MD PhD J. Robinson Singleton MD 《Muscle & nerve》2009,39(4):529-535
Reproducible neurophysiologic testing paradigms are critical for multicenter studies of neuropathy associated with impaired glucose regulation (IGR), yet the best methodologies and endpoints remain to be established. This study evaluates the reproducibility of neurophysiologic tests within a multicenter research setting. Twenty‐three participants with neuropathy and IGR were recruited from two study sites. The reproducibility of quantitative sudomotor axon reflex test (QSART) and quantitative sensory test (QST) (using the CASE IV system) was determined in a subset of patients at two sessions, and it was calculated from intraclass correlation coefficients (ICCs). QST (cold detection threshold: ICC = 0.80; vibration detection threshold: ICC = 0.75) was more reproducible than QSART (ICC foot = 0.52). The performance of multiple tests in one setting did not improve reproducibility of QST. QST reproducibility in our IGR patients was similar to reports of other studies. QSART reproducibility was significantly lower than QST. In this group of patients, the reproducibility of QSART was unacceptable for use as a secondary endpoint measure in clinical research trials. Muscle Nerve, 2008 相似文献
1000.